Table 2. Association between baseline characteristics and antitumor responses to olaparib.
| Characteristic | p | ||
|---|---|---|---|
| Platinum Status | Plt-S (N=65) | Plt-R (N=38) | |
| Median PTPI | 68.7w | 25.9w | p<0.0001 |
| CR/PR to olaparib | 23 (35%) | 5 (13%) | p=0.02 |
| Prior lines of chemo | 1 (N=15) | >1 (N=91) | |
| CR/PR to olaparib | 8 (53.3%) | 20 (23.5%) | p<0.005 |
| Platinum status and PTPI | Plt-S >24w PTPI (N=58) | Plt-R <24w PTPI (N=20) | |
| CR/PR to olaparib | 20 (34.5%) | 2 (10%) | p=0.04 |
| PTPI (independent of Plt status) | Pts with PTPI >52w (N=35) | Pts with PTPI <52w (N=59) | |
| CR/PR to olaparib | 15 (42%) | 11 (18%) | p=0.016 |
| BRCA1/2 status | BRCA1 (N=77) | BRCA2 (N=31) | |
| CR/PR to olaparib | 21 (27.6%) | 7 (27%) | p=0.31 |
| Breast cancer history | Prior BC (N=40) | Without (N=68) | |
| CR/PR to olaparib | 17 (26.5%) | 11 (29%) | p= 0.76 |
| Breast cancer chemotherapy | Chemo (N=20) | None (N=88) | |
| CR/PR to olaparib | 4 (22.2%) | 24 (28.5%) | p=0.64 |